Compare AVNT & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNT | WVE |
|---|---|---|
| Founded | 1927 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 1993 | 2015 |
| Metric | AVNT | WVE |
|---|---|---|
| Price | $32.75 | $15.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | ★ $45.67 | $29.94 |
| AVG Volume (30 Days) | 786.2K | ★ 13.9M |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $3,246,100,000.00 | $109,230,000.00 |
| Revenue This Year | $2.24 | N/A |
| Revenue Next Year | $2.35 | $16.00 |
| P/E Ratio | $25.97 | ★ N/A |
| Revenue Growth | 1.03 | ★ 103.75 |
| 52 Week Low | $27.48 | $5.28 |
| 52 Week High | $44.78 | $21.73 |
| Indicator | AVNT | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 66.16 | 53.14 |
| Support Level | $31.09 | $14.46 |
| Resistance Level | $31.82 | $18.50 |
| Average True Range (ATR) | 0.61 | 1.37 |
| MACD | 0.14 | -0.54 |
| Stochastic Oscillator | 95.05 | 18.48 |
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.